For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The price of Avidity Biosciences Inc (NASDAQ: RNA) closed at $30.35 in the last session, up 2.71% from day before closing price of $29.55. In other words, the price has increased by $2.71 from its previous closing price. On the day, 1.1 million shares were traded.
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.73 and its Current Ratio is at 15.73. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 20, 2024, initiated with a Buy rating and assigned the stock a target price of $72.
On November 26, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $67.
On September 24, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $59.Goldman initiated its Buy rating on September 24, 2024, with a $59 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Gallagher Kathleen P. sold 5,875 shares for $29.41 per share. The transaction valued at 172,807 led to the insider holds 50,554 shares of the business.
Gallagher Kathleen P. sold 5,875 shares of RNA for $188,918 on Feb 03 ’25. The Chief Program Officer now owns 50,554 shares after completing the transaction at $32.16 per share. On Feb 03 ’25, another insider, KATHLEEN GALLAGHER, who serves as the Officer of the company, bought 17,625 shares for $32.93 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 334.72 while its Price-to-Book (P/B) ratio in mrq is 2.55.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $19.18. The 50-Day Moving Average of the stock is -2.00%, while the 200-Day Moving Average is calculated to be -21.47%.
Shares Statistics:
A total of 119.89M shares are outstanding, with a floating share count of 111.07M. Insiders hold about 7.61% of the company’s shares, while institutions hold 104.00% stake in the company.
Earnings Estimates
Avidity Biosciences Inc (RNA) is currently under the scrutiny of 8.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.96, with high estimates of -$0.59 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$2.38 and -$4.99 for the fiscal current year, implying an average EPS of -$3.96. EPS for the following year is -$4.74, with 9.0 analysts recommending between -$2.34 and -$5.77.
